58 Participants Needed

Galeterone +/− Gemcitabine for Pancreatic Cancer

AH
YJ
AC
Overseen ByAaron Ciner, MD
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: University of Maryland, Baltimore
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot use other anti-cancer agents while participating. You also must not have received chemotherapy for at least 4 weeks before starting the trial.

What data supports the effectiveness of the drug Galeterone combined with Gemcitabine for pancreatic cancer?

Research shows that Galeterone, when combined with Gemcitabine, can significantly inhibit the growth and spread of pancreatic cancer cells in lab studies and reduce tumor growth in mice. This combination targets specific pathways that help cancer cells survive and resist treatment, making it a promising option for further development.12345

Is the combination of Galeterone and Gemcitabine safe for humans?

Gemcitabine is known to have a favorable side-effect profile, making it generally safe for use in humans. Galeterone, primarily studied for prostate cancer, is in phase III clinical development, indicating it has passed initial safety evaluations. However, specific safety data for the combination of Galeterone and Gemcitabine in humans is not provided in the available research.23678

What makes the drug combination of Galeterone and Gemcitabine unique for pancreatic cancer?

This drug combination is unique because Galeterone targets specific pathways (Mnk1/2-eIF4E and NF-κB) that are involved in pancreatic cancer progression and resistance to Gemcitabine, potentially enhancing the effectiveness of Gemcitabine and overcoming resistance in pancreatic cancer cells.123910

What is the purpose of this trial?

Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma

Research Team

AC

Aaron Ciner, MD

Principal Investigator

University of Maryland, Baltimore

Eligibility Criteria

This trial is for adults over 18 with advanced pancreatic adenocarcinoma who have tried at least two other treatments without success. They must be able to take oral medication, have a life expectancy of more than 12 weeks, and agree to use effective contraception. People with controlled brain metastasis may join, but not those with HIV, recent major surgery or radiation therapy, certain heart conditions, uncontrolled blood pressure issues, or active severe infections.

Inclusion Criteria

I can take care of myself and am up and about more than half of the day.
I have been diagnosed with pancreatic cancer.
You have confirmed spread of the disease that can be measured to be at least 1cm in size using a CT or MRI scan.
See 10 more

Exclusion Criteria

Your heart beats too slowly, less than 50 beats per minute.
I have not had a fainting spell or mini-stroke in the last year.
You are currently misusing alcohol or using illegal drugs.
See 23 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive galeterone alone or in combination with gemcitabine for pancreatic cancer

8 weeks
Daily oral doses of galeterone, weekly gemcitabine

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Long-term follow-up

Participants are monitored for overall survival and progression-free survival

Up to 100 months

Treatment Details

Interventions

  • Galeterone
  • Gemcitabine
Trial Overview The study tests the effectiveness of galeterone alone or combined with gemcitabine in treating metastatic pancreatic cancer. Participants will receive these medications to see if they help control the disease better than previous therapies they've had.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: galeterone+gemcitabineExperimental Treatment2 Interventions
daily dose galeterone and weekly dose of gemcitabine
Group II: galeteroneExperimental Treatment1 Intervention
galeterone orally once daily

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Recruited
540,000+

Findings from Research

Gemcitabine has changed the perception of pancreatic cancer treatment, showing good tolerability and low side effects, making it a viable option for combination therapies with drugs like cisplatin and 5-fluorouracil.
Combination regimens with gemcitabine and cisplatin have shown response rates between 11.4% and 58% and median survival times of 7.4 to 10 months, while gemcitabine with 5-FU has lower response rates and survival times, indicating the need for further optimization of treatment combinations.
Gemcitabine-based combination treatment of pancreatic cancer.Heinemann, V.[2022]
Galeterone and its analogs significantly inhibited the growth of pancreatic cancer cells, both in gemcitabine-naive and gemcitabine-resistant cell lines, suggesting they could overcome resistance to standard chemotherapy.
These compounds not only induced cell death and cell cycle arrest but also downregulated key signaling pathways and factors associated with cancer progression, leading to reduced cell migration and invasion, and showed promising tumor growth inhibition in animal models.
Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice.Kwegyir-Afful, AK., Murigi, FN., Purushottamachar, P., et al.[2018]
Gemcitabine is now considered a standard treatment for advanced pancreatic cancer due to its effectiveness and favorable side-effect profile.
While combinations of gemcitabine with other antitumor drugs and biological agents have shown promise in phase II trials, none have yet been established as an evidence-based standard treatment.
Present and future treatment of pancreatic cancer.Heinemann, V.[2022]

References

Gemcitabine-based combination treatment of pancreatic cancer. [2022]
Galeterone and its analogs inhibit Mnk-eIF4E axis, synergize with gemcitabine, impede pancreatic cancer cell migration, invasion and proliferation and inhibit tumor growth in mice. [2018]
Present and future treatment of pancreatic cancer. [2022]
Recent updates on the role of chemotherapy in pancreatic cancer. [2022]
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). [2022]
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells. [2022]
Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma. [2023]
Gemcitabine elaidate and ONC201 combination therapy inhibits pancreatic cancer in a KRAS mutated syngeneic mouse model. [2023]
[Gemcitabine: a new chemotherapy agent for solid cancers]. [2022]
10.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security